Date Title Description PDF
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
11 Dec 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 1 December and 8 December 2023 Download
01 Dec 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 24 November and 30 November 2023 Download
24 Nov 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 17 November and 23 November 2023 Download
17 Nov 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 10 November and 16 November 2023 Download
10 Nov 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 3 November and 9 November 2023 Download

Pages

Date Title Description PDF
26 Feb 2019 Información sobre resultados ROVI releases the presentation related to the full year 2018 results Download
26 Feb 2019 Información sobre resultados ROVI releases the press release related to the full year 2018 results Download
15 Feb 2019 Others on business performance and financial information ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets Download
09 Jan 2019 Others on business performance and financial information ROVI informs about the adquisition of Falithrom® for the German market Download
08 Jan 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the fourth quarter of 2018 Download

Pages